Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
October 25, 2013
Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development
Simona Rolla, Giada Ingoglia, Valentina Bardina, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
December 25, 2016
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity
Elisa Alchera, Simona Rolla, Chiara Imarisio, et al.
Clinical Science (London, England : 1979)
|
November 13, 2015
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice
Simona Rolla, Elisa Alchera, Chiara Imarisio, et al.
Expert Opinion on Drug Safety
|
June 23, 2017
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
Marinella Clerico, Carlo Alberto Artusi, Alessandra Di Liberto, et al.
International Journal of Molecular Sciences
|
May 5, 2017
Natalizumab in Multiple Sclerosis: Long-Term Management
Marinella Clerico, Carlo Alberto Artusi, Alessandra Di Liberto, et al.
Journal of Leukocyte Biology
|
August 7, 2014
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β
Simona Rolla, Valentina Bardina, Stefania De Mercanti, et al.
Journal of Neuroimmunology
|
November 21, 2017
Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
Simona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
January 29, 2016
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
Stefania De Mercanti, Simona Rolla, Angele Cucci, et al.
Frontiers in Immunology
|
March 17, 2022
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
Simona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Frontiers in Immunology
|
January 24, 2019
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
Andrea Iannello, Simona Rolla, Alessandro Maglione, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Journal of Immunology (Baltimore, Md. : 1950)
|
October 25, 2013
Acute-phase protein hemopexin is a negative regulator of Th17 response and experimental autoimmune encephalomyelitis development
Simona Rolla, Giada Ingoglia, Valentina Bardina, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
December 25, 2016
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity
Elisa Alchera, Simona Rolla, Chiara Imarisio, et al.
Clinical Science (London, England : 1979)
|
November 13, 2015
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice
Simona Rolla, Elisa Alchera, Chiara Imarisio, et al.
Expert Opinion on Drug Safety
|
June 23, 2017
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
Marinella Clerico, Carlo Alberto Artusi, Alessandra Di Liberto, et al.
International Journal of Molecular Sciences
|
May 5, 2017
Natalizumab in Multiple Sclerosis: Long-Term Management
Marinella Clerico, Carlo Alberto Artusi, Alessandra Di Liberto, et al.
Journal of Leukocyte Biology
|
August 7, 2014
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β
Simona Rolla, Valentina Bardina, Stefania De Mercanti, et al.
Journal of Neuroimmunology
|
November 21, 2017
Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
Simona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
January 29, 2016
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
Stefania De Mercanti, Simona Rolla, Angele Cucci, et al.
Frontiers in Immunology
|
March 17, 2022
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
Simona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Frontiers in Immunology
|
January 24, 2019
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
Andrea Iannello, Simona Rolla, Alessandro Maglione, et al.
Page
of 1